EXAMINE THIS REPORT ON HEMGENIX

Amount of suitable clients: CDEC talked over the uncertainty in the volume of patients with moderately serious to serious hemophilia B in Canada eligible for etranacogene dezaparvovec. Clinical specialists consulted by CADTH indicated that some patients who are categorised as having moderate or average disorder could possibly have a critical bleedi